FY2017 EPS Estimates for Charles River Laboratories International, Inc. (NYSE:CRL) Boosted by Analyst

Charles River Laboratories International, Inc. (NYSE:CRL) – SunTrust Banks upped their FY2017 earnings per share estimates for shares of Charles River Laboratories International in a research note issued to investors on Thursday, Zacks Investment Research reports. SunTrust Banks analyst S. Draper now expects that the medical research company will earn $5.15 per share for the year, up from their prior estimate of $5.10. SunTrust Banks has a “Buy” rating and a $113.00 price target on the stock. SunTrust Banks also issued estimates for Charles River Laboratories International’s Q4 2017 earnings at $1.26 EPS and FY2019 earnings at $6.47 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The firm had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.18 earnings per share.

A number of other research analysts have also recently commented on CRL. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price for the company in a report on Thursday, August 10th. BidaskClub upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Robert W. Baird reiterated a “buy” rating and issued a $114.00 price objective on shares of Charles River Laboratories International in a report on Friday, September 1st. Jefferies Group reiterated a “buy” rating and issued a $120.00 price objective on shares of Charles River Laboratories International in a report on Tuesday, September 12th. Finally, Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $106.63.

Charles River Laboratories International (CRL) traded down $2.22 during mid-day trading on Friday, hitting $102.07. 388,938 shares of the stock were exchanged, compared to its average volume of 379,364. The company has a market capitalization of $4,939.33, a PE ratio of 20.49, a P/E/G ratio of 1.66 and a beta of 0.89. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. Charles River Laboratories International has a 52-week low of $71.48 and a 52-week high of $119.05.

A number of large investors have recently added to or reduced their stakes in CRL. Teachers Advisors LLC lifted its position in Charles River Laboratories International by 5.0% in the 1st quarter. Teachers Advisors LLC now owns 124,069 shares of the medical research company’s stock worth $11,160,000 after buying an additional 5,874 shares during the last quarter. Eqis Capital Management Inc. lifted its position in Charles River Laboratories International by 10.3% in the 2nd quarter. Eqis Capital Management Inc. now owns 3,810 shares of the medical research company’s stock worth $385,000 after buying an additional 357 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in Charles River Laboratories International by 4.6% in the second quarter. Oregon Public Employees Retirement Fund now owns 17,199 shares of the medical research company’s stock valued at $1,740,000 after purchasing an additional 753 shares during the last quarter. LS Investment Advisors LLC lifted its position in Charles River Laboratories International by 17.1% in the second quarter. LS Investment Advisors LLC now owns 3,971 shares of the medical research company’s stock valued at $402,000 after purchasing an additional 580 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in Charles River Laboratories International by 3.3% in the second quarter. Louisiana State Employees Retirement System now owns 12,400 shares of the medical research company’s stock valued at $1,254,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 96.27% of the company’s stock.

In related news, insider Davide Molho sold 6,165 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. In the last three months, insiders have acquired 10,500 shares of company stock valued at $2,885 and have sold 1,012,147 shares valued at $1,591,514. Corporate insiders own 2.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/04/fy2017-earnings-forecast-for-charles-river-laboratories-international-inc-issued-by-suntrust-banks-crl.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply